PepGen Inc.

PepGen Inc.

NNASDAQ:PEPG
4.19
USD
-0.17
(-3.90%)
-1.06EPS
167.61MMarket Cap
Mar 10Next Earn
PepGen Inc.
NASDAQ:PEPG
(Nasdaq Stock Market)

Recent

price

4.19

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.53
-3.53
-2.91
-3.3
-2.85
-2.12
-1.06
Basic EPS, GAAP
-0.22
-2.99
-2.66
-3.01
-2.62
-1.94
-0.92
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.31
-1.56
7.58
4.55
3.64
2.14
1.49
Book Value per Share
-0.31
-1.56
7.58
4.55
3.64
2.14
1.49
Tangible Book Value per Share
8
8
24
24
32
42
69
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
1
5
5
5
Depreciation Expense
-2
-27
-69
-79
-90
-90
-73
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
9
130
167
95
107
138
95
Working Capital
- -
- -
19
17
16
14
12
LT Debt
10
133
180
108
119
147
103
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-54.59
-79.26
-67.39
-55.07
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
13
13
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
122
125
168

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
134
120
108
Cash, Cash Equivalents & STI
132
117
105
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
9
9
12
Payables & Accruals
4
4
6
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
258.15%
24.3%
Free Cash Flow
- -
298.51%
-1.17%
Net Income, GAAP
- -
305.07%
-0.36%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.63
-0.87
-0.66
-0.68
-2.85
2025
-0.92
-0.7
-0.52
-0.27
-2.12
2026
-0.26
-0.26
-0.28
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
PepGen Inc. PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company founded in 2018 and headquartered at 321 Harrison Avenue, Boston, Massachusetts, develops next-generation oligonucleotide therapeutics leveraging its proprietary Enhanced Delivery Oligonucleotide (EDO) platform to address severe neuromuscular and neurological diseases, including myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD). The company's lead candidates include PGN-EDODM1, an EDO peptide-conjugated phosphorodiamidate morpholino oligomer (PMO) in Phase 2 trials (FREEDOM2-DM1, recruiting; FREEDOM-DM1, enrollment completed) targeting splicing correction in DM1 patients aged 16-60; PGN-EDO51 in Phase 2 for exon 51-skipping amenable DMD patients; and PGN-EDO53 in preclinical development for DMD, with the EDO technology engineered for improved tissue penetration, cellular uptake, and nuclear delivery across muscle types and the central nervous system. PepGen operates primarily in the United States, focusing on rare genetic disorders with high unmet needs through its pipeline of disease-modifying therapies; it also supports custom oligonucleotide synthesis, preclinical development services including PK/PD studies and toxicology, and expertise in peptide-drug conjugates for blood-brain barrier crossing. In September 2025, PepGen closed a $115 million underwritten public offering of common stock priced at $3.20 per share, including the full exercise of underwriters' option for additional shares led by Leerink Partners and Stifel, with net proceeds funding ongoing clinical trials such as FREEDOM-DM1 and FREEDOM2-DM1, research expansion, working capital, and general corporate purposes; the company continues to advance discovery programs in additional neuromuscular and neurological indications while maintaining approximately 81 employees and leadership under President and CEO James McArthur.

Company News

  • PepGen: Upgrade To 'Buy' On PGN-EDODM1 Splicing Data Comeback And 2027 Milestones

  • PepGen Announces Pricing of $125 Million Public Offering

  • PepGen Announces Pricing of $125 Million Public Offering

  • PepGen: Stock Soars On DM1 Data, But Caution Warranted On Small Sample Sizes

  • PepGen Inc. (PEPG) Discusses FREEDOM2 Lowest Dose Cohort Safety, Splicing and vHOT Results Transcript

  • PepGen Announces Proposed $125.0 Million Public Offering of Common Stock

  • PepGen Stock Doubles in One Session - Here's Why

  • PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

  • PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures

  • PepGen, Inc. (NASDAQ:PEPG) Stock Now Rated “Moderate Buy” by Wall Street Analysts

  • PepGen, Inc. $PEPG Shares Bought by Squarepoint Ops LLC

  • ADAR1 Capital Management LLC Acquires New Shares in PepGen, Inc. $PEPG

  • PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

  • PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

  • PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

  • PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

  • PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program

  • PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

  • PepGen (PEPG) Upgraded to Buy: Here's What You Should Know

  • PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights